Acción Cidara Therapeutics (CDTX)
Empresa que cotiza en bolsa. Aquí tienes el precio, un resumen del negocio y lo que conviene saber sobre Cidara Therapeutics en septiembre 2026.
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Rendimiento del crecimiento a seis meses
Resumen del rendimiento de la acción
Calificación de los analistas
Analysts suggest holding CIDARA's stock as its target price is slightly lower than the current price.
Salud financiera
Cidara Therapeutics is showing strong financial performance, highlighted by solid cash flow and book value.
Ve más acciones descargando la app GRATIS
Solo toma 60 segundos.
¿Por qué invertir con Nemo?
Cero comisiones
Opera acciones, ETF y más sin comisiones. Conserva una mayor parte de tus ganancias.
Confiable y regulado
Parte del grupo Exinity desde 2015, con más de un millón de clientes en todo el mundo.